All In MedTech

FDA Clearance Tracker · P200010-S008

Guardant360 CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 11, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 11, 2022

Approved

Time to decision

120 days

Received Apr 13, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P200010-S008
Device name
Guardant360 CDx
Applicant location
Redwood City, CA
Received
Apr 13, 2022
Decided
Aug 11, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P200010

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval for expanding the indications for use to include the companion diagnostic claim to identify non-small cell lung cancer patients with ERBB2 activating mutations (SNVs and exon 20 insertions) for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).

Source documents

Other decisions for Guardant Health, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.